Cargando…

Identifying the serious clinical outcomes of adverse reactions to drugs by a multi-task deep learning framework

Adverse Drug Reactions (ADRs) have a direct impact on human health. As continuous pharmacovigilance and drug monitoring prove to be costly and time-consuming, computational methods have emerged as promising alternatives. However, most existing computational methods primarily focus on predicting whet...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Haochen, Ni, Peng, Zhao, Qichang, Liang, Xiao, Ai, Di, Erhardt, Shannon, Wang, Jun, Li, Yaohang, Wang, Jianxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449791/
https://www.ncbi.nlm.nih.gov/pubmed/37620651
http://dx.doi.org/10.1038/s42003-023-05243-w
_version_ 1785095037479026688
author Zhao, Haochen
Ni, Peng
Zhao, Qichang
Liang, Xiao
Ai, Di
Erhardt, Shannon
Wang, Jun
Li, Yaohang
Wang, Jianxin
author_facet Zhao, Haochen
Ni, Peng
Zhao, Qichang
Liang, Xiao
Ai, Di
Erhardt, Shannon
Wang, Jun
Li, Yaohang
Wang, Jianxin
author_sort Zhao, Haochen
collection PubMed
description Adverse Drug Reactions (ADRs) have a direct impact on human health. As continuous pharmacovigilance and drug monitoring prove to be costly and time-consuming, computational methods have emerged as promising alternatives. However, most existing computational methods primarily focus on predicting whether or not the drug is associated with an adverse reaction and do not consider the core issue of drug benefit-risk assessment—whether the treatment outcome is serious when adverse drug reactions occur. To this end, we categorize serious clinical outcomes caused by adverse reactions to drugs into seven distinct classes and present a deep learning framework, so-called GCAP, for predicting the seriousness of clinical outcomes of adverse reactions to drugs. GCAP has two tasks: one is to predict whether adverse reactions to drugs cause serious clinical outcomes, and the other is to infer the corresponding classes of serious clinical outcomes. Experimental results demonstrate that our method is a powerful and robust framework with high extendibility. GCAP can serve as a useful tool to successfully address the challenge of predicting the seriousness of clinical outcomes stemming from adverse reactions to drugs.
format Online
Article
Text
id pubmed-10449791
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104497912023-08-26 Identifying the serious clinical outcomes of adverse reactions to drugs by a multi-task deep learning framework Zhao, Haochen Ni, Peng Zhao, Qichang Liang, Xiao Ai, Di Erhardt, Shannon Wang, Jun Li, Yaohang Wang, Jianxin Commun Biol Article Adverse Drug Reactions (ADRs) have a direct impact on human health. As continuous pharmacovigilance and drug monitoring prove to be costly and time-consuming, computational methods have emerged as promising alternatives. However, most existing computational methods primarily focus on predicting whether or not the drug is associated with an adverse reaction and do not consider the core issue of drug benefit-risk assessment—whether the treatment outcome is serious when adverse drug reactions occur. To this end, we categorize serious clinical outcomes caused by adverse reactions to drugs into seven distinct classes and present a deep learning framework, so-called GCAP, for predicting the seriousness of clinical outcomes of adverse reactions to drugs. GCAP has two tasks: one is to predict whether adverse reactions to drugs cause serious clinical outcomes, and the other is to infer the corresponding classes of serious clinical outcomes. Experimental results demonstrate that our method is a powerful and robust framework with high extendibility. GCAP can serve as a useful tool to successfully address the challenge of predicting the seriousness of clinical outcomes stemming from adverse reactions to drugs. Nature Publishing Group UK 2023-08-24 /pmc/articles/PMC10449791/ /pubmed/37620651 http://dx.doi.org/10.1038/s42003-023-05243-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhao, Haochen
Ni, Peng
Zhao, Qichang
Liang, Xiao
Ai, Di
Erhardt, Shannon
Wang, Jun
Li, Yaohang
Wang, Jianxin
Identifying the serious clinical outcomes of adverse reactions to drugs by a multi-task deep learning framework
title Identifying the serious clinical outcomes of adverse reactions to drugs by a multi-task deep learning framework
title_full Identifying the serious clinical outcomes of adverse reactions to drugs by a multi-task deep learning framework
title_fullStr Identifying the serious clinical outcomes of adverse reactions to drugs by a multi-task deep learning framework
title_full_unstemmed Identifying the serious clinical outcomes of adverse reactions to drugs by a multi-task deep learning framework
title_short Identifying the serious clinical outcomes of adverse reactions to drugs by a multi-task deep learning framework
title_sort identifying the serious clinical outcomes of adverse reactions to drugs by a multi-task deep learning framework
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449791/
https://www.ncbi.nlm.nih.gov/pubmed/37620651
http://dx.doi.org/10.1038/s42003-023-05243-w
work_keys_str_mv AT zhaohaochen identifyingtheseriousclinicaloutcomesofadversereactionstodrugsbyamultitaskdeeplearningframework
AT nipeng identifyingtheseriousclinicaloutcomesofadversereactionstodrugsbyamultitaskdeeplearningframework
AT zhaoqichang identifyingtheseriousclinicaloutcomesofadversereactionstodrugsbyamultitaskdeeplearningframework
AT liangxiao identifyingtheseriousclinicaloutcomesofadversereactionstodrugsbyamultitaskdeeplearningframework
AT aidi identifyingtheseriousclinicaloutcomesofadversereactionstodrugsbyamultitaskdeeplearningframework
AT erhardtshannon identifyingtheseriousclinicaloutcomesofadversereactionstodrugsbyamultitaskdeeplearningframework
AT wangjun identifyingtheseriousclinicaloutcomesofadversereactionstodrugsbyamultitaskdeeplearningframework
AT liyaohang identifyingtheseriousclinicaloutcomesofadversereactionstodrugsbyamultitaskdeeplearningframework
AT wangjianxin identifyingtheseriousclinicaloutcomesofadversereactionstodrugsbyamultitaskdeeplearningframework